WallStreetZenWallStreetZen

NASDAQ: TTOO
T2 Biosystems Inc Stock

$4.79+0.10 (+2.13%)
Updated Jun 12, 2024
TTOO Price
$4.79
Fair Value Price
N/A
Market Cap
$42.12M
52 Week Low
$2.60
52 Week High
$70.00
P/E
-0.42x
P/B
-1.12x
P/S
2.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.18M
Earnings
-$45.65M
Gross Margin
-117%
Operating Margin
-566.42%
Profit Margin
-636.1%
Debt to Equity
-1.66
Operating Cash Flow
-$47M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TTOO Overview

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TTOO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TTOO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TTOO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
TTOO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more TTOO due diligence checks available for Premium users.

Be the first to know about important TTOO news, forecast changes, insider trades & much more!

TTOO News

Valuation

TTOO fair value

Fair Value of TTOO stock based on Discounted Cash Flow (DCF)
Price
$4.79
Fair Value
-$0.18
Undervalued by
2,742.95%
TTOO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TTOO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.42x
Industry
39.56x
Market
30.03x

TTOO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.12x
Industry
4.33x

TTOO's financial health

Profit margin

Revenue
$2.1M
Net Income
-$13.5M
Profit Margin
-656.7%
TTOO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TTOO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$24.8M
Liabilities
$62.5M
Debt to equity
-1.66
TTOO's short-term liabilities ($56.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TTOO's short-term assets ($15.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TTOO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TTOO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$11.7M
Investing
$0.0
Financing
$2.2M
TTOO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TTOO vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
TTOO$42.12M+2.13%-0.42x-1.12x
NOTV$44.67M-3.37%-0.62x0.22x
OCX$36.75M+0.36%-0.54x3.17x
DRIO$34.41M-11.54%-0.68x0.44x
XGN$34.23M-2.48%-1.81x1.71x

T2 Biosystems Stock FAQ

What is T2 Biosystems's quote symbol?

(NASDAQ: TTOO) T2 Biosystems trades on the NASDAQ under the ticker symbol TTOO. T2 Biosystems stock quotes can also be displayed as NASDAQ: TTOO.

If you're new to stock investing, here's how to buy T2 Biosystems stock.

What is the 52 week high and low for T2 Biosystems (NASDAQ: TTOO)?

(NASDAQ: TTOO) T2 Biosystems's 52-week high was $70.00, and its 52-week low was $2.60. It is currently -93.16% from its 52-week high and 84.23% from its 52-week low.

How much is T2 Biosystems stock worth today?

(NASDAQ: TTOO) T2 Biosystems currently has 8,792,950 outstanding shares. With T2 Biosystems stock trading at $4.79 per share, the total value of T2 Biosystems stock (market capitalization) is $42.12M.

T2 Biosystems stock was originally listed at a price of $71,600.00 in Aug 7, 2014. If you had invested in T2 Biosystems stock at $71,600.00, your return over the last 9 years would have been -99.99%, for an annualized return of -65.63% (not including any dividends or dividend reinvestments).

How much is T2 Biosystems's stock price per share?

(NASDAQ: TTOO) T2 Biosystems stock price per share is $4.79 today (as of Jun 12, 2024).

What is T2 Biosystems's Market Cap?

(NASDAQ: TTOO) T2 Biosystems's market cap is $42.12M, as of Jun 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

T2 Biosystems's market cap is calculated by multiplying TTOO's current stock price of $4.79 by TTOO's total outstanding shares of 8,792,950.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.